Bicara Therapeutics Cash Flow Statement
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.50+0.24 (+1.39%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bicara Therapeutics free cash flow
In fiscal 2025, Bicara Therapeutics generated -$106.8 million of operating cash flow and spent $280,000 on capital expenditures. That left free cash flow of -$107.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Bicara Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -137.95M | -68.00M | -51.98M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 105.00K | 56.00K | 19.00K |
| Stock-Based Compensation | 15.01M | 7.40M | 1.90M |
| Change in Working Capital | 5.28M | -16.85M | -914.00K |
| Operating Cash Flow | -106.83M | -74.75M | -45.63M |
| Capital Expenditures | -280.00K | -71.00K | -586.00K |
| Investing Cash Flow | -318.45M | -9.00K | -586.00K |
| Financing Cash Flow | 32.26M | 334.03M | 272.50M |
| Net Change in Cash | -393.03M | 259.27M | 226.28M |
| Free Cash Flow | -107.11M | -74.82M | -46.21M |
This table shows 3 annual periods of Bicara Therapeutics's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BCAX's reporting calendar. What is a cash flow statement?